Strong association of single nucleotide polymorphisms in BRCA1, ATM, and CHEK2 with breast cancer susceptibility in a sub-population of Iranian women.
ATM
BRCA1
CHEK2
Breast cancer
Polymorphism
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
22 Oct 2024
22 Oct 2024
Historique:
received:
18
07
2024
accepted:
30
09
2024
medline:
22
10
2024
pubmed:
22
10
2024
entrez:
22
10
2024
Statut:
aheadofprint
Résumé
Breast cancer (BC) is the most prevalent malignancy in females worldwide. Mutations in the DNA repair pathway genes contribute to a significant increase in BC risk. The present study aimed to assess the frequency of polymorphisms in BRCA1, ATM, and CHEK2 genes and their association with BC susceptibility in the Kurdish population from the West of Iran. In the present case-control study, the distribution of single nucleotide polymorphisms (SNPs) in CHEK2 (rs17879961), ATM (rs28904921), and BRCA1 (rs80357906, rs1555576855, rs1555576858, and rs397509247) genes were investigated in 335 BC cases and 354 healthy-matched controls by Taqman allelic discrimination assay. The chi-square goodness-of-fit test was employed for the assessment of Hardy-Weinberg Equation. Relative risk and odds ratios were calculated based on the Koopman asymptotic score and the Baptista-Pike method, respectively. Also, the sensitivity and specificity of each polymorphism were assessed using the Wilson-Brown test and a P-value < 0.05 indicating significant differences between the two groups in all assessments. Data showed there was a strong association between rs397509247 (OR = 7.53, 95% CI 1.88-90.91, p = 0.004), rs1555576858 (OR = 10.53, 95% CI 0.01-0.51, p = 0.0005), and rs80357906 (OR = 6.33, 95% CI 0.05-0.043, p < 0.0001) in BRCA1 gene and rs17879961 (OR = 3.52, 95% CI 0.084-0.946, p = 0.02) in CHEK2 gene, with BC risk in the population of interest. Among these, rs28904921 in ATM gene demonstrated the strongest association (OR = 72.66, 95% CI 0.007-0.214, p < 0.0001). This suggests that these SNPs, particularly rs28904921, are significantly associated with an increased risk of BC in the studied population. Our results indicated that BRCA1, ATM, and CHEK2 polymorphisms have a high frequency in the Iranian breast cancer population, with some mutant allele frequencies being much higher than those reported in other populations. We have also provided a simple, multiplex, rapid, and accurate genotyping assay that is useful in clinical settings.
Sections du résumé
BACKGROUND
BACKGROUND
Breast cancer (BC) is the most prevalent malignancy in females worldwide. Mutations in the DNA repair pathway genes contribute to a significant increase in BC risk. The present study aimed to assess the frequency of polymorphisms in BRCA1, ATM, and CHEK2 genes and their association with BC susceptibility in the Kurdish population from the West of Iran.
METHODS
METHODS
In the present case-control study, the distribution of single nucleotide polymorphisms (SNPs) in CHEK2 (rs17879961), ATM (rs28904921), and BRCA1 (rs80357906, rs1555576855, rs1555576858, and rs397509247) genes were investigated in 335 BC cases and 354 healthy-matched controls by Taqman allelic discrimination assay. The chi-square goodness-of-fit test was employed for the assessment of Hardy-Weinberg Equation. Relative risk and odds ratios were calculated based on the Koopman asymptotic score and the Baptista-Pike method, respectively. Also, the sensitivity and specificity of each polymorphism were assessed using the Wilson-Brown test and a P-value < 0.05 indicating significant differences between the two groups in all assessments.
RESULTS
RESULTS
Data showed there was a strong association between rs397509247 (OR = 7.53, 95% CI 1.88-90.91, p = 0.004), rs1555576858 (OR = 10.53, 95% CI 0.01-0.51, p = 0.0005), and rs80357906 (OR = 6.33, 95% CI 0.05-0.043, p < 0.0001) in BRCA1 gene and rs17879961 (OR = 3.52, 95% CI 0.084-0.946, p = 0.02) in CHEK2 gene, with BC risk in the population of interest. Among these, rs28904921 in ATM gene demonstrated the strongest association (OR = 72.66, 95% CI 0.007-0.214, p < 0.0001). This suggests that these SNPs, particularly rs28904921, are significantly associated with an increased risk of BC in the studied population.
CONCLUSION
CONCLUSIONS
Our results indicated that BRCA1, ATM, and CHEK2 polymorphisms have a high frequency in the Iranian breast cancer population, with some mutant allele frequencies being much higher than those reported in other populations. We have also provided a simple, multiplex, rapid, and accurate genotyping assay that is useful in clinical settings.
Identifiants
pubmed: 39436532
doi: 10.1007/s10549-024-07503-7
pii: 10.1007/s10549-024-07503-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Kermanshah University Of Medical Sciences, Kermanshah, Iran
ID : 96259
Organisme : Kermanshah University Of Medical Sciences, Kermanshah, Iran
ID : 96259
Organisme : Kermanshah University Of Medical Sciences, Kermanshah, Iran
ID : 96259
Organisme : Kermanshah University Of Medical Sciences, Kermanshah, Iran
ID : 96259
Organisme : Kermanshah University Of Medical Sciences, Kermanshah, Iran
ID : 96259
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Siasi E, Solimani M (2020) Associations of single nucleotide polymorphism in miR-146a gene with susceptibility to breast cancer in the Iranian female. Asian Pac J Cancer Prev 21(6):1585
doi: 10.31557/APJCP.2020.21.6.1585
pubmed: 32592352
pmcid: 7568866
Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME (2018) Epidemiology and histopathology of breast cancer in Iran versus other Middle Eastern countries. Middle East J Cancer 9(3):243–251
Amani F, Fouladi N, Zakeri A, Tabrizian S, Enteshari-Moghaddam A, Barzegari S (2020) Changing trend of breast cancer in Ardabil’s people by age group, grading, and gender during 2003–2016. Middle East J Cancer
Lee A, Mavaddat N, Wilcox AN, Cunningham AP, Carver T, Hartley S et al (2019) BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. Genet Med 21(8):1708–1718
doi: 10.1038/s41436-018-0406-9
pubmed: 30643217
pmcid: 6687499
Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y et al (2017) Risk factors and preventions of breast cancer. Int J Biol Sci 13(11):1387
doi: 10.7150/ijbs.21635
pubmed: 29209143
pmcid: 5715522
Armstrong N, Ryder S, Forbes C, Ross J, Quek RG (2019) A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol 11:543
doi: 10.2147/CLEP.S206949
pubmed: 31372057
pmcid: 6628947
Jara L, Morales S, De Mayo T, Gonzalez-Hormazabal P, Carrasco V, Godoy R (2017) Mutations in BRCA1, BRCA2 and other breast and ovarian cancer susceptibility genes in Central and South American populations. Biol Res 50(1):35
doi: 10.1186/s40659-017-0139-2
pubmed: 28985766
pmcid: 6389095
Bąk A, Janiszewska H, Junkiert-Czarnecka A, Heise M, Pilarska-Deltow M, Laskowski R et al (2014) A risk of breast cancer in women-carriers of constitutional CHEK2 gene mutations, originating from the North-Central Poland. Hereditary cancer in clinical practice 12(1):1–5
doi: 10.1186/1897-4287-12-10
Weidner AE, Liggin ME, Zuniga BI, Tezak AL, Wiesner GL, Pal T (2020) Breast cancer screening implications of risk modeling among female relatives of ATM and CHEK2 carriers. Cancer 126(8):1651–1655
doi: 10.1002/cncr.32715
pubmed: 31967672
Gorodetska I, Kozeretska I, Dubrovska A (2019) BRCA genes: the role in genome stability, cancer stemness and therapy resistance. J Cancer 10(9):2109
doi: 10.7150/jca.30410
pubmed: 31205572
pmcid: 6548160
Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP et al (2020) Pan-cancer analysis of BRCA1 and BRCA2 genomic alterations and their association with genomic instability as measured by genome-wide loss of heterozygosity. JCO Precis Oncol 4:442–465
doi: 10.1200/PO.19.00345
pubmed: 32903788
Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N et al (2020) Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants. Commun Biol 3(1):1–9
doi: 10.1038/s42003-020-01301-9
Mustofa MK, Tanoue Y, Tateishi C, Vaziri C, Tateishi S (2020) Roles of Chk2/CHEK2 in guarding against environmentally induced DNA damage and replication-stress. Environ Mol Mutagen 61(7):730–735
doi: 10.1002/em.22397
pubmed: 32578892
Weigelt B, Bi R, Kumar R, Blecua P, Mandelker DL, Geyer FC, et al (2018) The landscape of somatic genetic alterations in breast cancers from ATM germline mutation carriers. J Nat Cancer Inst 110(9):1030–1034
Chou W-C, Hu L-Y, Hsiung C-N, Shen C-Y (2015) Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway. Carcinogenesis 36(8):832–840
doi: 10.1093/carcin/bgv079
pubmed: 26025911
Decker B, Allen J, Luccarini C, Pooley KA, Shah M, Bolla MK et al (2017) Rare, protein-truncating variants in ATM, CHEK2 and PALB2, but not XRCC2, are associated with increased breast cancer risks. J Med Genet 54(11):732–741
doi: 10.1136/jmedgenet-2017-104588
pubmed: 28779002
Petridis C, Arora I, Shah V, Megalios A, Moss C, Mera A et al (2019) Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years. Breast Cancer Res 21(1):58
doi: 10.1186/s13058-019-1143-y
pubmed: 31060593
pmcid: 6501320
Bermisheva M, Takhirova Z, Bogdanova N, Khusnutdinova E (2014) Frequency of CHEK2 gene mutations in breast cancer patients from Republic of Bashkortostan. Mol Biol 48(1):46–51
doi: 10.1134/S0026893314010026
Nejati-Azar A, Alivand MR (2018) miRNA 196a2 (rs11614913) & 146a (rs2910164) polymorphisms & breast cancer risk for women in an Iranian population. Pers Med 15(04):279–289
doi: 10.2217/pme-2017-0088
Miller S, Dykes D, Polesky H (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215
doi: 10.1093/nar/16.3.1215
pubmed: 3344216
pmcid: 334765
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J clinicians 68(6):394–424
Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G et al (2019) Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol 37(6):453
doi: 10.1200/JCO.18.01631
pubmed: 30526229
Rowley SM, Mascarenhas L, Devereux L, Li N, Amarasinghe KC, Zethoven M et al (2019) Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility. Genet Med 21(4):913–922
doi: 10.1038/s41436-018-0277-0
pubmed: 30254378
Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE et al (2017) Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers. BMC Cancer 17(1):438
doi: 10.1186/s12885-017-3422-2
pubmed: 28637432
pmcid: 5480128
Sadeghi F, Asgari M, Matloubi M, Ranjbar M, Yousefi NK, Azari T et al (2020) Molecular contribution of BRCA1 and BRCA2 to genome instability in breast cancer patients: review of radiosensitivity assays. Biol Proced Online 22(1):1–28
doi: 10.1186/s12575-020-00133-5
Mahdavi M, Nassiri M, Kooshyar MM, Vakili-Azghandi M, Avan A, Sandry R et al (2019) Hereditary breast cancer; genetic penetrance and current status with BRCA. J Cell Physiol 234(5):5741–5750
doi: 10.1002/jcp.27464
pubmed: 30552672
Abou-El-Naga A, Shaban A, Ghazy H, Elsaid A, Elshazli R, Settin A (2018) Frequency of BRCA1 (185delAG and 5382insC) and BRCA2 (6174delT) mutations in Egyptian women with breast cancer compared to healthy controls. Meta Gene 15:35–41
doi: 10.1016/j.mgene.2017.11.002
Yang Y, Shu X, Shu X-o, Bolla MK, Kweon S-S, Cai Q, et al. Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. EBioMedicine. 2019;48:203–11.
Cragun D, Bonner D, Kim J, Akbari M, Narod S, Gomez-Fuego A et al (2015) Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. Breast Cancer Res Treat 151(1):169–176
doi: 10.1007/s10549-015-3374-7
pubmed: 25868867
pmcid: 4503247
Levy-Lahad E, Catane R, Eisenberg S, Kaufman B, Hornreich G, Lishinsky E et al (1997) Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. Am J Hum Genet 60(5):1059
pubmed: 9150153
pmcid: 1712434
Parvin S, Islam MS, Al-Mamun MMA, Islam MS, Ahmed MU, Kabir ER et al (2017) Association of BRCA1, BRCA2, RAD51, and HER2 gene polymorphisms with the breast cancer risk in the Bangladeshi population. Breast Cancer 24(2):229–237
doi: 10.1007/s12282-016-0692-5
pubmed: 27068824
Fatahi M, Mojtahedi Z, Karim AN, Taleei AA, Banani SJ, Ghaderi A (2009) Analysis of BRCA1 and BRCA2 mutations in southern Iranian breast cancer patients. Arch Iran Med. 2009 Nov;12(6):584–7
Saleh-Gohari N, Mohammadi-Anaie M, Kalantari-Khandani B (2012) BRCA1 gene mutations in breast cancer patients from Kerman Province, Iran. Iran J Cancer Prev 5(4):210
pubmed: 25352972
pmcid: 4209574
Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB et al (2011) Rare variants in the ATMgene and risk of breast cancer. Breast Cancer Res 13(4):R73
doi: 10.1186/bcr2919
pubmed: 21787400
pmcid: 3236337
Apostolou P, Papasotiriou I (2017) Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer Targets Ther 9:331
doi: 10.2147/BCTT.S111394